Stockreport

Amy Rudolph, PhD, Joins Thryv Therapeutics' Board of Directors to Support Portfolio Progression into Heart Failure [Yahoo! Finance]

Thryv Holdings, Inc.  (THRY) 
PDF inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced the appointment of Amy Rudolph, P [Read more]